About
PreciseDx, founded in 2019 in New York, uses AI to analyze patient-specific pathology data and deliver personalized risk assessments for breast cancer.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 4
Founders / team· 1
Funding history
- 2024-08Series B$21M
Investors · GenHenn Capital Venture, Labcorp, Eventide, Quest DiagnosticsSource · SVTR Weekly #067
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- PreciseDx
AI analysis of pathology data for personalized breast cancer risk assessment
Series B · $21M · 2024-08
$21M
United States
BusinessLatest roundTotal raisedDate- Ataraxis AI
AI-based test that analyzes patient data to assess breast cancer risk and guide treatment decisions
Series A · $24M · 2025-03
$24M - RadiantGraph
AI that helps health plans analyze data to personalize member engagement
Undisclosed · $16M · 2024-10
$16M - Delfina
AI analysis of pregnant women's health data to predict potential risks before complications arise
Undisclosed · $17M · 2025-02
$17M
Europe
BusinessLatest roundTotal raisedDate- Aignostics
Turns complex multimodal pathology data into transformative insights
Undisclosed · $55M · 2024-12
$55M - Deciphex
Digital pathology software using AI to help pathologists analyze medical samples more efficiently
Series C · $32M · 2025-01
$32M - Rivia
Data platform using AI to organize, analyze and drive clinical trial data intelligence
Series A · $21M · 2026-03
$21M
Other / unspecified
BusinessLatest roundTotal raisedDate- Cureskin
App using AI analysis to deliver dermatologist-designed personalized skincare and haircare plans
Series B · $20M · 2024-03
$20M - Nucleai
Uses AI to analyze pathology images for medical research and clinical diagnosis
Undisclosed · $14M · 2024-04
$14M - HoneyNaps
Uses advanced algorithms to analyze sleep data and provide accurate diagnostic insights
Series B · $12M · 2024-05
$12M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
39 Life Sciences deals in the last 24 months · 21 at a nearby stage · 35 in NYC Metro
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 19 at a nearby stage · 31 in NYC Metro
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 14 at a nearby stage · 22 in NYC Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 11 at a nearby stage · 20 in NYC Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 12 at a nearby stage · 15 in NYC Metro
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 11 at a nearby stage · 14 in NYC Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.